Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-7172 tablets, a new anti-tumor small molecule inhibitor developed by the company, with no similar drugs approved for market in China or abroad [1] Group 1: Company Developments - The company has announced the approval of the clinical trial for HRS-7172 tablets [1] - HRS-7172 tablets represent the company's independent research and development efforts in the field of oncology [1] - Cumulative research and development investment for the HRS-7172 project has reached approximately 28.41 million yuan [1] Group 2: Industry Context - Currently, there are no similar drugs approved for market in both domestic and international markets [1]